A double blind, placebo controlled, randomized clinical trial to evaluate the efficacy and safety of the VirulinaÂ® along with standard treatment as per hospital protocol for the treatment of novel coronavirus (COVID-19).

atural Solutions0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Either male or female of age range 18-70 years.
•2. Recent history of contact with Covid-19 positive people and are advised to be quarantined or has symptoms which include cough, fever with or without chills and difficulty in breathing (Time interval between symptoms onset and randomization to be not more than 7 days)
•3. Patients with laboratory confirmation of infection with SAARS-CoV-2 by positive RT-PCR (within 48 hrs prior to randomization)
•Subjects willing to give written informed consent and come for a regular follow up
•4. Subjects willing to abide by and comply with the study protocol

•1. Patients presenting severe multisystemic symptoms compatible with advanced Covid-19 and intercurrent acute or severe chronic diseases (i.e. active cancer).
•2. Presence of acute hypoxic respiratory failure
•3. Requires Intensive care unit (ICU) care for management of ongoing clinical status
•4. Severe infection, defined as need for invasive or non- invasive ventilator support
•5. Inability to intake or tolerate oral medication
•6. Category 6 or 5 based on modified 7-category ordinal
•scale of clinical status
•7. Clinical prognostic non-survival, palliative care, and have no response to supportive treatment within three hours of admission
•8. Pregnant subjects

发起方

atural Solutions